Total
0
Shares
Amplia Therapeutics - CEO and MD, John Lambert - The Market Herald
CEO and MD, John Lambert
Source: Amplia Therapeutics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Amplia Therapeutics (ATX) completes the design for a Phase 2 clinical trial in first-line pancreatic cancer patients
  • The clinical trial of its Focal Adhesion Kinase inhibitor, AMP945, will be added to chemotherapy with the standard of care currently used to treat the majority of newly diagnosed pancreatic cancer patients
  • In the trial, AMP945 will be administered orally to patients prior to each dose of their standard chemotherapy
  • Amplia says it plans to initiate patient recruitment at Australian sites in the first quarter of 2022
  • Amplia Therapeutics closed down 2.50 per cent at 19.5 cents

Amplia Therapeutics (ATX) has completed the design for a Phase 2 clinical trial in first-line pancreatic cancer patients.

The clinical trial of its Focal Adhesion Kinase inhibitor, AMP945, will be added to chemotherapy with gemcitabine and nabpaclitaxel – the standard of care currently used to treat the majority of newly diagnosed pancreatic cancer patients.

In the trial, AMP945 will be administered orally to patients prior to each dose of their standard chemotherapy.

The company said conducting the phase 2 clinical trial in first-line patients is expected to expedite recruitment and provide the best opportunity to detect any efficacy signal from the addition of AMP945 to chemotherapy.

“Clinical evaluation of AMP945 as part of a first-line treatment for pancreatic cancer significantly de-risks the program and makes the drug relevant for a much larger patient base.” said Dr John Lambert, CEO of Amplia Therapeutics.

 “If we are able to see positive signs that AMP945 improves the leading current treatment option we will commence discussions with regulators and potential partners concerning future trials required to support product approval.”

Amplia says it plans to initiate patient recruitment at Australian sites in the first quarter of 2022, which is expected to take around 18 to 24 months.

Amplia Therapeutics closed down 2.50 per cent at 19.5 cents.

ATX by the numbers
More From The Market Herald
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon - The Market Herald

" ImpediMed (ASX:IPD) initiates SOZO heart failure program

ImpediMed (IPD) has initiated its SOZO heart failure program at Advocate Health Care’s Heart Institute in Chicago.    
Invex Therapeutics (ASX:IXC) - Chairman, Jason Loveridge - The Market Herald

" Invex Therapeutics (ASX:IXC) pens agreement for commercialisation of Presedin

Invex Therapeutics (IXC) has signed an agreement for the commercialisation of its treatment for neurological conditions caused by intracranial pressure.
LBT Innovations (ASX:LBT) - CEO and MD, Brent Barnes - The Market Herald

" LBT Innovations (ASX:LBT) subsidiary appoints US distributor

LBT Innovations (LBT) 50 per cent owned joint venture company, Clever Culture System (CCS), has appointed Thermo Fisher Scientific as its US distributor.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett - The Market Herald

" Paradigm Biopharma (ASX:PAR) receives FDA feedback for knee osteoarthritis drug

Paradigm Biopharmaceuticals (PAR) has received feedback from US Food and Drug Administration (FDA) for its knee osteoarthritis drug.